The neurofood phase 1 concludes with productions with higher concentrations of Gaba and Ergotioneina

• The Neurofood R&D project aims to develop products that favor normal neurocognitive development and their functional validation in healthy and patient individuals
• In Phase 1 of Neurofood (2018-2019) Hifas da Terra has developed novel production systems that generate greater amounts of GABA and Ergotixeine to reach levels with therapeutic action in the final extracts of various species of mushrooms
• In addition, HDT has conducted analytical studies that verify higher concentrations of active substances at the neurocognitive level in certain fungal species
• The results obtained have allowed progress in the formulation that will be used in the clinical trial that will begin in the coming months (phase 2) in collaboration with the Foltra Cuevas y Cía Foundation

He NEUROFOOD R&D Project, which aims to advance knowledge and prevention of neurocognitive problems, has just concluded its first phase with excellent results. Not only have they Optimized productive aspects that will allow raising substances of interest in the extract or final product, but also have verified active levels of substances that intervene in memory and learning in various species of fungi.

Throughout this Phase 1 (2018-2019), Hifas da Terra has analyzed and compared mycological species on which there was already prior bilbiography based on its content in γ-aminobutyric acid (GABA) and ergotinein; Substances whose function and repercussions are studied in cognitive deterioration, dementia, Alzheimer's and other neurodegenerative diseases.

Gaba and Ergotioneina

The León hair (Hericium erinaceus), he Shiitake (Edodes lentinula) and he Coprinus (Coprinus comatus) They are some of the species that have stood out in the analytical tests, showing optimal levels of both substances. The results have also been conclusive in the tests carried out on final product where, for example, the Hifas León Da Terra Mecha Excerpt It already shows representative concentrations of GABA.

As explained by researchers from the R&D department, other “widely studied” substances such as Herithenonas and the ERINACINAS which are also present naturally in the León hair.

The objective, they add, is to verify therapeutic concentrations of all substances of interest both in the fungus and in their by -products and, from there, establish productive protocols and processes that affect their concentration ratios.

For this they have developed SNovel isysms of production of raw materials based on fungi that generate greater amounts of GABA and Ergotinein. These interventions carried out in the initial phases will allow "richer" productions in compounds of interest to health care.

Phase 2 Neurofood

These initial conclusions have already served to advance in the formulation of the product that will be tested in the Clinical trial (phase 2) which will begin in the coming months and in which, in addition to Hifas da Terra, the Foltra and Cuevas and Cía Foundation will participate.

In the trial, the impact of functional foods and food supplements developed with mushrooms, chests and algae will be evaluated within the framework of internationally recognized scales for the monitoring of neurocognitive problems.

Summary

Thanks to the conclusions of phase 1 of the Neurofood R&D project, Hifas da Terra advances in the development and validation of a functional product aimed at maintaining normal cognitive abilities. In 2020 the results of the clinical trial that will be carried out in the coming months will be analyzed. It will evaluate aspects related to attention, memory, learning, etc.